Roth Capital lowered the firm’s price target on Capricor Therapeutics (CAPR) to $12 from $31 and keeps a Buy rating on the shares. The FDA’s Complete Response Letter – CRL – for Deramiocel well ahead of the PDUFA timeline of August 31 was a “surprise” as all eyes now turn to HOPE-3 top-line data expected in Q3, though the firm still expects positive HOPE-3 data and potential BLA approval in mid-2026, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics price target lowered to $16 from $20 at Alliance Global
- Capricor Therapeutics Stock (CAPR) Plummets 40% on FDA Rejection
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Capricor Therapeutics price target lowered to $20 from $43 at Piper Sandler
- Capricor Therapeutics price target lowered to $22 from $30 at Cantor Fitzgerald